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¤  Maternal immunization  
¤  History of development 
¤  Different antigens / options 
¤  Where are we today? 
¤  Different vaccines  
¤  Cost-effectiveness 
¤  Take home messages 
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INTRODUCTION & BURDEN 
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Group B streptococcal diseases in 
neonates	  
 
§  Since the 1970s, leading cause of life-
threatening infections in newborns 
§  Neonatal illness/death 
§  Long-term disabilities 
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Group B streptococcal diseases in 
neonates	  
 
§  Since the 1970s, leading cause of life-
threatening infections in newborns 
§  Neonatal illness/death 




     0.3-3 per 1,000 live birth 
 
LOD  
    0.4-0.5 per 1,000 live birth 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases in 
the 1990s, U.S. 
   Consensus   
   guidelines: 
- Screening  
-Risk-based 
Group B Strep 
Association 
formed  
  1st ACOG & AAP 
   statements 
           CDC draft  
guidelines published 
S. Schrag, New Engl J Med 2000 
Schrag S. et al. N Engl J Med 2002; 347:233-9 
 
Screening >50%  
more effective  
than RF 
 
No effect on GBS LOD 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases, U.S. 
Incidence of early- and late-onset invasive group B streptococcal disease in 
















































department of health and human services
Centers for Disease Control and Prevention
Recommendations and Reports November 19, 2010 / Vol. 59 / No. RR-10
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr
Prevention of Perinatal Group B 
Streptococcal Disease
Revised Guidelines from CDC, 2010
Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html
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European strategies 
for prevention of GBS EOD 
§  Intrapartum antibioprophylaxis recommended 
§ Screening-based strategy 
§  Spain, 1998, 2003, revised 2012 
§  France, 2001 
§  Belgium, 2003, revised 2015 
§  Germany, 1996, revised 2008 
§  Switzerland, 2007  
§ Risk-based strategy 
§  UK, the Netherlands, Denmark 
 
§  No guidelines 
§  Bulgaria, … 
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GBS still the leader ! 
§  GBS remains leading cause of EO sepsis & 
meningitis 
§  Up to 60 % of occurring among women with 
negative antenatal screening 
à highlighting limitation with screening and IAP 
§  IAP has no effect on incidence of GBS LOD 
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Maternal GBS immunization 
	  	  	  	  	  INTR I   
Could maternal immunization be an 
alternative ? 
 
§  Protection against both EOD & LOD ? 
§  Bypassing concerns related to antimicrobial 
resistance ? 
§  Cost-effectiveness ? 
§  Adjunctive to screening & IAP ? 
11	  Congres SocBePed 2015-PM 	  	  	  	  INTRODUCTION         IMMUNIZATION          ANTIGENS          TODAY         CONCLUSION            
1887, Noccard-Mollereau, bovine mastitis 
1933, Group B Antigen  
1964, severe neonatal sepsis, Eickhoff et al N Eng J 
med 
Ø 	  	  1970,	  N°1	  in	  neonatal	  infec0ons	  
Gram positive cocci  
   β-hemolytic 
   Encapsulated à 1 of major virulence factors 
 	  
10 capsular serotypes (Ia, Ib, II-IX) 
 
Numerous surface proteins (α- and β-C, 
rib, Sip, pilus islands 1, 2a & 2b, etc) 	  
 
Streptococcus agalactiae or GBS 
Rebecca Lancefield 1895-1981 
	  	  	  	  	  INTR I   12	  Congres SocBePed 2015-PM 	  	  	  	  INTRODUCTION         IMMUNIZATION          ANTIGENS          TODAY         CONCLUSION            
Distribution (%) of capsular types of GBS isolated 
in neonatal disease 
(DEVANI project, 2008-2011, EU Fund FP7 programme) 
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Ia Ib II III IV V 
EOD LOD 
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Distribution (%) of capsular types of GBS isolated in 
Belgium from different groups of patients (1998-2007) 










Ia	   Ib	   II	   III	   IV	   V	   VI	  -­‐	  VIII	   NT	  
EOD	   LOD	   Adults	  
236 neonatal EOD; 64 neonatal LOD; 721 adults 
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Stages in the pathogenesis of GBS 




adhesion to epithelial cells different 










-  C5a peptidase 




IL1, IL6, TNF α, 
PGE2, TxA2 ,   
Brain barrier 




Phagocytes cells, CPS 
Antibodies, Complement 
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Stages in the pathogenesis of GBS 
neonatal EOD : Bacterial & individual factors 
GBS  
pathogenesis 
Colonization : adhesion to epithelial cells 










-  C5a peptidase 
-  ….. 
Phagocytes cells, CPS 
Antibodies, Complement 
GBS vaccine 
« nearly within reach » 





	  	  	  	  	  INTR I   16	  Congres SocBePed 2015-PM 	  	  	  	  INTRODUCTION         IMMUNIZATION          ANTIGENS          TODAY         CONCLUSION            
MATERNAL IMMUNIZATION 
History of vaccine development 
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Lancefield’s observations 
§  Demonstration of protection against lethal GBS 
infection in a mouse model by antibodies to the CPS 
of GBS 




	  	  	  	  IM UNIZ I
Background 
Long-standing data supports protection of maternal anti-CPS Ab	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Background 
Long-standing data supports protection of maternal anti-CPS Ab	  
§  Correlate between maternal low level of CPS type Ab  
(III, Ia & Ib) at time of delivery and risk for development 
of GBS EOD 
§  Human serum containing sufficient concentrations of 
Ia, Ib, II, III and V CPS-specific IgG promotes efficient 
opsonization & phagocytosis of homologous strain in 
vitro and protection from experimental infection in vivo. 
 
Baker C et Kasper D, 1976, NEJM 
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Background 
First generation of CPS vaccine	  
¤ Disappointment from studies of uncoupled first 
generation purified native GBS CPS vaccines in 
healthy adults 
¤ Demonstration of  feasibility of vaccine prevention of 
GBS disease 
¤ Need for improvement of immunogens 
¤ Success story of polysaccharide-protein conjugate 
vaccine technology in preventing Hi b and 
S.pneumoniae infections in infants 
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Background	  
§  Expectation of polysaccharide-protein 
glycoconjugates 
§  T cell-dependent response 
§  Immunological memory & long term protection 
§  Predominantly IgG1 subclass à improved 
transplacental transport 




	  	  	  	  IM UNIZ I
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Maternal vaccination allows 
infant protection 	  
§  Placental transfer increases markedly > 32 weeks 
 
 
	  	  	  	  IM UNIZ I
Vaccine for pregnant women: 
 Likely the most effective, sustainable and cost 
effective approach 






NN fusion protein 
	  	  	   TIGENS 
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GBS Vaccines, since the 1980s   
Challenges 
Native capsular polysaccharide vaccines (1st gen) 
§  10 serotypes 
§  Different distributions 
§  EOD, LOD, invasives infections in adults 
§  Geographically, along time, ATB  pressure 










Ia	   Ib	   II	   III	   IV	   V	   VI	  -­‐	  VIII	   NT	  
EOD	   LOD	   Adults	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GBS Vaccines, since the 1980s   
Challenges 
Native capsular polysaccharide vaccines (1st gen) 
§  10 serotypes 
§  Different distributions 
§  EOD, LOD, invasives infections in adults 
§  Geographically, along time, ATB  pressure 
Conjugated vaccines (2nd gen)  
(Channing laboratory, Harvard medical school, Boston) 
§  CPS III-Tetanus Toxoid 
§  Monovalent Ia, Ib, II and V CPS –TT 
§  Tested for immunogenicity in healthy adults 
§  Multivalent conjugated vaccines Ia, Ib, (II), III 
(and V) 
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GBS Vaccines, since the 1980s   
Challenges 
Capsular polysaccharide - TT vaccines 
Capsular polysaccharide – CRM197 vaccines 
(Second generation) 
 
§  Dosage and route of administration 
§  Immune response 
§  Duration of immunity and protection 
§  Safety studies 
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GBS Protein-based Vaccine 
§  Ag = Surface proteins 
§  Cross protection against different serotypes 
§  Better immunogenicity 
§  Humoral response T-cell dependent   
    = long lasting immunity 
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GBS Vaccines, since the 1980s   
Challenges 
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Protein  Protective Ab  associated serotypes 
  (in mouse) 
Alpha-like proteins   
    Alpha  Yes    Ia, Ib et II 
    Alp1      Ia 
    Rib  Yes    III 
    Alp2  Yes    V, VIII 
    Alp3  Yes    V, VIII 
Beta C protein  Yes    Ib 
C5a peptidase  Yes    All 
Sip (1999)  Yes    All 
BPS  Yes    All 
Sip = Surface Immunogenic Protein (Brodeur, Martin, Québec)  
BPS= Groupe B Protective surface Protein 
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Protein-based Vaccines 
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Protein-based Vaccines 
Reverse vaccinology approach 
Knowledge of complete GBS genome 
 
§  Comparaison of genomes from 8 different 
GBS serotypes (Novartis) 
D.Maione et al, Science 2006 
§  312 surface proteins were cloned 
§  4  provide a high protective humoral response in 
mouse 
§  Sip and 3 others 
§  The 3 other proteins = « pilus like structures » 
§  PI 1, PI 2a & 2b 
 
	  	  	   TIGENS 
29	  Congres SocBePed 2015-PM 	  	  	  	  INTRODUCTION         IMMUNIZATION          ANTIGENS          TODAY         CONCLUSION            
GBS « pilus like structure » 
§    
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GBS « pilus like structure » 
§  Highly immunogenic proteins 
§  Elicit protective and functional (opsonophagocytosis) 
antibodies 
§  Virulence factor 
§  Adhesion 
§  Transcytose through cells 
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Protein-based Vaccines 
GBS-NN fusion protein 
From Rib and AlphaC surface proteins of GBS 
§  Based on novel vaccine epitopes identified in the N-terminal 
regions of the Rib and AlphaC surface-proteins of GBS 
§  Vaccine candidate is a non-glycosylated fusion protein 
 
 







Rib and AlphaC surface proteins of GBS GBS-NN Fusion protein 
Immunodominant Repeats Non-immunodominant Highly Immunogenic 
Cell Host & Microbes 2, 427-434, 2007 
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Protein-based Vaccines 
GBS-NN fusion protein 
From Rib and AlphaC surface proteins of GBS 
§  Based on novel vaccine epitopes identified in the N-terminal 
regions of the Rib and AlphaC surface-proteins of GBS 
§  Vaccine candidate is a non-glycosylated fusion protein 
§  Highly immunogenic and anti-GBS-NN antibodies more 
protective than antibodies to full-length proteins 
 
 
	  	  	   TIGENS 
A novel protein-only, single component, GBS  
vaccine covering 95% of clinical isolates 
33	  Congres SocBePed 2015-PM 	  	  	  	  INTRODUCTION         IMMUNIZATION          ANTIGENS          TODAY         CONCLUSION            
Protein-based Vaccines 
GBS-NN fusion protein 
	  	  	   TIGENS 
Anti-Alpha 
Anti-Rib 
•  Strong clinical correlation exists 
between naturally occurring maternal 
and neonatal levels of anti-Rib and 
anti-Alpha antibodies 
•  Strong correlation exists between 
levels of neonatal anti-Alpha (OR 
0.0007) and Anti-Rib (OR 0.002) and 
invasive GBS infection 
•  Anti-GBS-NN more protective than 
antibodies against full length Rib 
and Alpha in animal models 
Arch Dis Child Fetal Neonatal Ed 91:F403-408, 2006 
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Protein-based Vaccines 
Vaccination with GBS-NN protects against lethal 
challenge with GBS Ia, Ib, II & III in adult mice 
	  	  	   TIGENS 
Cell Host & Microbe 2, 427-434, 2007 
Mice immunized with GBS-NN in alum, boosted after 4 weeks and challenged 2 
weeks later. 
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Protein-based Vaccines 
Anti-GBS-NN antisera prevents GBS invasion of 
epithelial cells 
	  	  	   TIGENS 
Cell Host & Microbe 2, 427-434, 2007 
microbial surface proteins. To analyze this hypothesis, we
studied Streptococcus pyogenes M protein, a major viru-
lence factor with a variable N-terminal region targeted by
opsonizing antibodies and a conserved C repeat region
(Kehoe, 1994). Our analysis was focused on the exten-
sively studied M22 protein.
Antibodies elicited by intact pureM22were analyzed for
reactivity with different parts of the protein. For this pur-
pose, we used three long peptides derived from M22:
the M22-N, Sap22, and C22 peptides (Figure 4A). Previ-
ous work had shown that antibodies to M22-N and
Sap22 promoted opsonization, while antibodies to C22
did not (Carlsson et al., 2003). Interestingly, antibodies
to intact M22 reacted well with C22 but showed little or
no reactivity with M22-N or Sap22 (Figure 4B, left). This
lack of reactivity with M22-N and Sap22 was not caused
by a technical problem, because anti-(M22-N) reacted
with M22-N, as expected (Figure 4B, right) and anti-
Sap22 reacted with Sap22 (data not shown). Importantly,
the M22-N and Sap22 peptides retain the structure of the
corresponding domains in M22, as shown by their ability
to bind ligands (Johnsson et al., 1999; Morfeldt et al.,
2001), so absence of antibodies to these peptides reflects
absence of antibodies to the N-terminal part of M22.
These data indicate that the N-terminal part of M22, which
is targeted by opsonizing antibodies, is nonimmunodomi-
nant. This conclusion is supported by a study of the M6
protein, which has a centrally located B repeat region
that apparently is immunodominant (Fischetti and Wind-
els, 1988). Thus, the data obtained with M22 corroborate
those obtained with the GBS proteins Rib and a, and
they focus interest on nonimmunodominant regions as
targets for protective antibodies.
Of note, the immunodominance of the C repeat region in
M22 cannot be explained by a molar excess of repeats,
because the size of the repeat region is similar to that of
the nonimmunodominant N-terminal part of M22. Simi-
larly, the data on Rib and a in Figure 1 indicate that the im-
munodominance of the repeats in these proteins cannot
simply be explained by molar excess. An interesting alter-
native hypothesis predicts that both M protein and Rib/
a exploit a specific mechanism, by which the repeat re-
gions of these proteins actively interfere with the formation
of antibodies to the N-terminal regions.
Concluding Remarks
The work reported here shows that the N-terminal regions
of the GBS proteins Rib and a are nonimmunodominant
when present within the intact proteins but elicit good
Figure 3. Antibodies to RibN-aN Prevent
Invasion of Human Epithelial Cells
(A) Role of Rib and a in epithelial cell invasion.
A Rib-negative mutant of strain BM110 (left)
and an a-negative mutant of strain A909 (right)
were compared with the corresponding wild-
type (WT) bacteria for ability to invade cells of
the human cervical cell line ME180.
(B) Inhibition of epithelial cell invasion by anti-
(RibN-aN). Bacteria of strain BM110 (left) or
A909 (right) were preincubated with rabbit
anti-(RibN-aN) or with preimmune serum be-
fore use in the invasion assay.
All data in (A) and (B) are based on three dif-
ferent experiments. SDs and p values are indi-
cated.
Figure 4. The N-Terminal Part of the S. pyogenesM22 Protein
Is Nonimmunodominant
(A) Schematic representation of theM22 protein (Carlsson et al., 2003).
The N-terminal hypervariable region of M22 binds the human comple-
ment inhibitor C4BP, while an adjacent semivariable region binds hu-
man IgA. The C-terminal part of M22 includes the conserved C repeat
region. Three long peptides (M22-N, Sap22, and C22) were derived
from these regions, as indicated. The two peptides M22-N and
Sap22 specifically bind C4BP and IgA, respectively.
(B) Dot blot analysis. The rabbit antisera indicated were used to detect
M22-derived peptides immobilized on membranes. The amounts of
peptide applied are indicated to the left. Rabbit anti-M22 reacted al-
most exclusively with the C22 peptide (left blot). This lack of reactivity
was not due to a technical problem, because antiserum raised toM22-
N reacted with M22-N and also showed some reactivity with the over-
lapping Sap22 peptide, as expected (right blot). Bound antibodies
were detected by incubation with radiolabeled protein G, followed by
autoradiography. Very similar results were obtained with two rabbit
antisera of each type.
Cell Host & Microbe 2, 427–434, December 2007 ª2007 Elsevier Inc. 431
Cell Host & Microbe
Nonimmunodominant Regions in Protein Vaccine
Potential Implications for 
pathogenesis and 
prevention of  
invasive disease by 
mucosal anti-NN IgG 
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CANDIDATE VACCINES 
What is ongoing ? 
CRM-Conjugate CPS 
NN Fusion protein 
Cost effectiveness studies 
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Novartis GBS Vaccine 
Trivalent glycoconjugate vaccine 
§  CRM conjugated CPS Ia, Ib and III 
§  Trivalent conjugate coverage: 79 % globally 
§  Phase I completed, and Phase II ongoing 
Planned start 2015 
(EU/US/Global) 
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Minervax GBS Vaccine 
Single component NN fusion protein 
§  Anticipated coverage : 95% of isolates 
§  Clinical trial in healthy adults : Q2-2015 
§  EU funding FP7 Programme HEALTH for the 
development of a novel innovative GBS vaccine 
candidate 
§  Other sources of funding 
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GBS Maternal immunization 
Would it be cost-effective? 
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GBS Maternal immunization 
Would it be cost-effective? 
§  Cases prevented, 
§  Deaths averted, 
§  Life-years saved 
§  Quality-adjusted life-years (QALYs) gained 
§  Costs of  
§  Acute care for infants with GBS disease 
§  Chronic care for those with long term disability 
§  Immunization per person 
§  Assuming 85% coverage 
§  Prevention of an additional 899 cases of GBS and 
an additional 35 deaths among infants in the US 
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GBS Maternal immunization 
Would it be cost-effective? 
In conclusion  
Routine maternal immunization with a trivalent (Ia, Ib 
and III) vaccine at week 28 of pregnancy  
§  As an adjunct to screening and IAP 
§  May address an important unmet public health need in 
the US 
§  And further reduce the burden of GBS disease during 
infancy (EO and LOD) 
§  May be comparable in cost-effectiveness to several other 
vaccines recently approved to use in children and 
adolescents 
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GBS Maternal immunization 
Would it be cost-effective? 
	  	  	  	  	  T
Trivalent (Ia, Ib and III) glycoconjugate vaccine 
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GBS Maternal immunization 
Would it be cost-effective? 
§  In low and middle income countries:  
§  no screening-based IAP strategy 
§  +/-  RF-based IAP strategy 
§  Comparison of 4 strategies 
§  Doing nothing 
§  Maternal GBS vaccination 
§  RF-based IAP 
§  Maternal GBS vaccination + RF-based IAP 
§  Assuming 50-90% coverage and 75% of women vaccinated 
§  Vaccination / Doing nothing  à prevents 30-54% of cases 
§  RF-based IAP / Doing nothing  à prevents 10% of cases 
§  Vaccination +  RF-based IAP   à prevents 48% of cases 
à Substantial reduction of the burden of infant GBS disease in 
South Africa and would be cost-effective by WHO-guidelines 
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Editorial
Introduction:  Addressing  the  challenge  of  group  B  streptococcal  disease
Towards the end of the 20th century, progress in vaccine devel-
opment technology led to the availability of conjugate vaccines
for the most common causes of bacterial sepsis and meningitis in
children including vaccines for Haemophilus influenzae type b, the
pneumococcus and meningococcus serotypes A, C, W-135 and Y
[1]. Recently a new vaccine for meningococcus serogroup B devel-
oped by reverse vaccinology has been approved by the EMA. These
advances in technology have been great advances in our ability to
prevent sepsis and meningitis in children.
On a parallel track, programmatic advances in the use of existing
vaccines have provided the opportunity to protect vulnerable pop-
ulations such as newborn infants and pregnant women. Although
maternal immunization with tetanus toxoid in developing coun-
tries has been recommended by WHO  for decades and has greatly
reduced the risk of neonatal tetanus, more recently immunization
of pregnant women has been recommended against influenza to
protect the mother and the infant [2]. In fact, influenza immuniza-
tion in pregnancy has been shown to have broad benefits to the
mother and infant including increased birth weight in infants born
to immunized mothers [2]. In addition, maternal pertussis immu-
nization during pregnancy is now routinely recommended in the
United States to protect newborns against this disease. Since infant
immunization with pertussis can not provide effective protection
to the infant until their second dose at four months of age and since
the highest morbidity and mortality of pertussis is in the first few
months of life, this was felt to be the only possible strategy to pro-
vide protection to these infants [3]. Importantly, these programs
have demonstrated not only that maternal immunization during
pregnancy is feasible, but also that it is a safe and effective vac-
cination strategy. However, the tetanus, influenza and pertussis
programs all have one thing in common: these programs utilize
vaccines that were developed and initially evaluated for use in
adults and older children and were then introduced into pregnant
women at a later date. To date, no vaccine has been approved and
licensed for use that has been specifically designed and targeted for
use in pregnant women.
With vaccine advances that have controlled or virtually elim-
inated the risk of Hib, pneumococcal and meningococcal disease
in children, the major cause of meningitis and sepsis in childhood
in developed countries and a major cause in all countries is now
the group B streptococcus or Streptococcus agalactiae (GBS). The
most widely recognized GBS disease occurs in newborns and young
infants with approximately half of this disease occurring within the
first hours of life (early onset disease) and the remainder occurring
after the first week but within the first 90 days (late onset disease).
The disease incidence varies by country but can be as high as 3 cases
per 1000 live births [4] with mortality ranging between 10 and 50%
even with modern neonatal intensive care [5]. It is important to
note that while programs which screen pregnant women for GBS
colonization and then institute intrapartum antibiotic prophylaxis
in those testing positive for GBS have been effective in reducing the
risk of early onset diseases in infants most notably in the US,  these
programs are not optimal both because the coordinated high level
of health care management is not available in developing countries
and importantly these programs only impact early onset GBS dis-
ease and have no effect on the remaining 50% of the total disease
burden in infants accounted for by late onset disease.
Moreover, there is increasing evidence that GBS is a cause
of maternal infections including urinary tract infections and
chorioamnionitis which result in maternal morbidity during preg-
nancy and are a risk factor for prematurity [6]. Recently it has been
demonstrated that selected strains of GBS lacking the hemolysin
repressor CovR/S accelerate failure of the amniotic barrier and
allow GBS to penetrate the chorioamniotic membrane barrier and
gain access to the fetus [7]. This provides a pathophysiologic basis
for the previously demonstrated ability of GBS  to cause maternal
chorioamnionitis as well as to gain access to the fetus and cause
early onset disease.
Thus a GBS vaccine administered to pregnant women during
pregnancy would have the potential to prevent the morbidity of
GBS infections in the mother with their associated risk of prematu-
rity as well as to protect the infant against both early and late onset
disease through passive acquired antibody.
It has been known for some time that antibody against the GBS
capsular polysaccharide in mothers is correlated with decreased
risk of disease in their infants [8]. This protection is serotype spe-
cific with most disease being due to serotypes Ia, Ib, III and to a
lesser extent serotype V. Novartis Vaccines has developed a vac-
cine containing CRM197 conjugates of capsular polysaccharides Ia,
Ib and III. This vaccine has been shown to be safe and immuno-
genic in both pregnant and non-pregnant women and to provide
IgG anti-capsular antibody to infants born to immunized pregnant
women through transplacental passive transfer (Novartis Vaccines
and Diagnostics, unpublished data). Preparation for a phase III effi-
cacy trial to evaluate the effectiveness of maternal immunization
with a trivalent GBS glycol-conjugate in the prevention of both early
and late onset GBS disease in their newborns is now underway.
In July 2012, a symposium was  held in Siena, Italy to discuss
the nature of Group B Streptococcal disease in the newborn, to
review current global disease burden and to discuss the need to
effective interventions which would be applicable in both devel-
oped and developing countries. The papers in this supplement to
0264-410X/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
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•  Introduction, Rappuoli & Black 
•  GBS Revi w, Carol Baker 
•  Overview GBS epi emiology, Paul Heath 
•  GBS epidemi  and vaccine needs, Melin &  Efstratiou  
•  GBS epidemiolog  in dev lo ping c untries 
•  IAP in USA et Vaccine implications, S.Schrag & Verani 
•  GBS maternal vaccines Past Present and Future, Chen & Kasper 
•  GBS Public awareness etc 
•  Pr vention  through Vaccinatio , M. Edwards 
•  GBS Vacci ation in pregnancy, P. F rrieri 
•  GBS vaccine Phas  III trial 
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GBS	  vacci e	  -­‐	  C nclusion	  
§  CPS-glycoconjugate vaccine 
§  3 to 5-valent glycoconjugate vaccine (Ia, Ib, II, 
III and V) 
§  CPS-CRM197 / Pili vaccine 
§  NN-fusion protein vaccine 
§  Immunogenicity 
§  Safety 
§  Efficacy determination ongoing 
§  Impact on colonization : unknown 
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Maternal	  GBS	  immuniza0on	  
Conclusion	  
§  Immunization at 28-32 weeks 
§  Prevention at least 85% of invasive 
GBS disease in neonates and young 
infants 
§  Potential reduction  
§  of incidence of maternal invasive GBS 
infection 
§  of premature births, stillbirths related 
to GBS infection 
§  Cost-effective in high and low 
income countries 
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